Five Prime Therapeutics Inc (FPRX) 2019年年度报告「NASDAQ」.pdf

《Five Prime Therapeutics Inc (FPRX) 2019年年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《Five Prime Therapeutics Inc (FPRX) 2019年年度报告「NASDAQ」.pdf（156页珍藏版）》请在三个皮匠报告上搜索。

1、 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,DC 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31,2019or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For t

2、he transition period from to Commission File Number:001-36070 Five Prime Therapeutics,Inc.(Exact name of registrant as specified in its charter)Delaware 26-0038620(State or other jurisdiction ofincorporation or organization)(IRS EmployerIdentification No.)111 Oyster Point BoulevardSouth San Francisc

3、o,California 94080(415)365-5600(Address,including zip code,and telephone number,including area code,of registrants principal executive offices)Securities registered pursuant to Section 12(b)of the Act:Title of Each Class Trading Symbol(s)Name of Each Exchange on Which RegisteredCommon Stock,par valu

4、e$0.001 per share FPRX The Nasdaq Stock Market LLCSecurities registered pursuant to Section 12(g)of the Act:NoneIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check mark if the registrant is not required to fil

5、e reports pursuant to Section 13 or 15(d)of the Act.Yes No Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for suchshorter period that the registrant was required

6、 to file such reports),and(2)has been subject to such filing requirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during thepreceding